Prospective Evaluation of Vitagel for Reduction in Blood Loss and Pain Following Unilateral Total Knee Arthroplasty

NCT ID: NCT01027286

Last Updated: 2012-11-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 108 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-07-31
• Study Completion Date: 2010-06-30

Brief Summary

Vitagel® is an FDA approved class III medical device. It is a surgical hemostat, which has been shown to control bleeding during orthopaedic, cardiac, hepatic, and general surgical procedures. The product is a thrombin/collagen suspension which works in combination with the patient's own plasma to form a fibrin/collagen clot.

The present prospective, randomized controlled trial is designed to evaluate the efficacy of Vitagel® for reducing blood loss and pain in patients managed with unilateral total knee arthroplasty (TKA). It is hypothesized that the use of Vitagel® may lead to less blood filled knees, and thus to a greater improvement in postoperative pain scores when compared to the control group. The two arms of the study will include:

1. experimental group in which Vitagel® is used unilateral TKA

2. control group representing our current standard of care (no Vitagel®)

A comparison of the functional and clinical results between these two groups will be conducted using several outcome measures including the KOOS, SF-12 version2 and pain scores through the previously IRB approved OrthoMidas registry. The primary variable of interest is blood loss, based on hemoglobin drop during the postoperative hospital stay. Of secondary interest will be; 1) pain levels in the PACU, 2) pain scores for all postoperative days, 3) average pain for the entire hospital stay, 4) length of stay, 5) patient satisfaction at discharge, 4 weeks postoperative, and 12 weeks postoperative, and 6) functional scores at 4 and 12 weeks postoperative.

Detailed Description

This is a prospective, single-center, randomized, double-blinded, clinical trial involving three orthopaedic surgeons who perform total knee replacement. The proposed study is optimal for obtaining clinical and functional comparisons between TKA surgical procedures utilizing conventional practices (control) and TKA utilizing Vitagel®, a surgical hemostat used to control bleeding and facilitate healing. The study will include patients that are receiving a unilateral primary TKA.

Fifty cases will be assigned to each arm of the study (total 100 cases). This sample size was estimated using an alpha of 0.05 (conventional for all studies) and a beta of 0.80 (recommended for superiority studies). The standard deviation is based on a study conducted by the PI at the Cleveland Clinic in an IRB approved retrospective project in 2007, and will provide in excess of 80 percent statistical power in detecting less than a 100 ml difference in blood loss between the two groups.

The study will be conducted at the Cleveland Clinic (Cleveland, OH). The patients will not be informed of their treatment assignment, and the research investigator making observations and recording the data postoperatively will also be blinded to their treatment assignment. The placement of patients into treatment arms will be based on random drawing of sealed envelopes. An assessment of blinding will be conducted at the conclusion of the study by asking patients what treatment they think that they received.

Data will be collected at four timepoints, including preoperatively, during the hospital stay, 4 weeks postoperatively, and 12 weeks postoperatively. Preoperative data collected will include baseline SF-12, KOOS, hemoglobin and hematocrit levels, and pain scores. Data collected in the hospital will include hemoglobin and hematocrit levels, pain scores, narcotics usage, length of stay, and patient satisfaction at discharge. The SF-12, KOOS, pain scores, and patient satisfaction will be collected utilizing the 4 week (±2 weeks) standard of care postoperative visit. Patients are not always seen at the 12 week (±4 weeks) postoperative timepoint as standard of care. To collect these data, patients will be mailed the SF-12, KOOS, pain scores, patient satisfaction, and blinding assessment questionnaires. Patients not responding to the initial mailer will be contacted by phone and sent a second packet of questionnaires.

Conditions

Arthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Vitagel

Group Type: EXPERIMENTAL

Vitagel

Intervention Type: DEVICE

Vitagel applied just prior to closure during primary total knee arthroplasty

Control

No Vitagel used.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Vitagel

Vitagel applied just prior to closure during primary total knee arthroplasty

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Age: 18 - 85 years
• Sex: Both male and female will be included. The male-to-female ratio will depend upon the patient population.
• Stable Health: At the time of surgery based on physical examination and medical history.
• Patient exhibited preoperative radiographic evidence of joint degeneration consistent with TKA that could not have been treated in non-operative fashion.
• Patient had severe knee pain and disability due to degenerative joint disease.
• Patient or patient's legal representative has signed the Informed Consent form. The patient is capable of making informed decisions regarding his/her healthcare.

Exclusion Criteria

• Patients with history of liver disease. Patients with liver dysfunction from cirrhosis or hepatitis may have impaired production of factors in the clotting cascade which may make these individuals more prone to bleed, especially with the use of anticoagulants. For this reason, these patients will also be excluded from this study if a baseline INR if greater than 1.3.
• Patients allergic to materials of bovine origin.
• Patients predonating autologous blood.
• Patients with a preoperative platelet count of less than 100,000.
• Patients undergoing bilateral or revision surgery.
• Evidence of bleeding or metabolic - based hemolytic disorder (hemophilia or anticoagulation use), or hypercoaguable disorder.
• Previous history of infection in the affected joint.
• Peripheral vascular disease.
• Patient was a poor compliance risk - treated for ethanol or drug abuse, physical or mental handicap, etc.
• Patients with a previous history of venous thromboembolism, or other reason for requiring anticoagulation other than ASA 325 mg po BID and mechanical compression.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Orthovita d/b/a Stryker

INDUSTRY

Sponsor Role: collaborator

The Cleveland Clinic

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Wael K Barsoum, MD

Role: PRINCIPAL_INVESTIGATOR

The Cleveland Clinic

Locations

The Cleveland Clinic

Cleveland, Ohio, United States

Countries

United States

References

Bloomfield MR, Klika AK, Molloy RM, Froimson MI, Krebs VE, Barsoum WK. Prospective randomized evaluation of a collagen/thrombin and autologous platelet hemostatic agent during total knee arthroplasty. J Arthroplasty. 2012 May;27(5):695-702. doi: 10.1016/j.arth.2011.09.014. Epub 2011 Oct 27.

Reference Type: RESULT

PMID: 22035976 (View on PubMed)

Other Identifiers

09-548

Identifier Type: -

Identifier Source: org_study_id